Dietary beta-carotene, vitamin C and E intake and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC)
What's New: July 2026 Update TRIUMPH-4 confirmed as final: 28.7% weight loss at 68 weeks in 445 participants peer-reviewed Phase 3 data, December 2025 TRIUMPH-1 CONFIRMED (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients the pivotal general obesity trial met all primary and key secondary endpoints TRIUMPH-1 extension: In a prespecified 104-week extension, patients reached 30.3% average weight loss weight loss does not plateau at 80 weeks TRANSCEND-T2D-1 CONFIRMED (topline March 2026, published June 2026): First dedicated Phase 3 diabetes trial -2.0% HbA1c and 16.8% weight loss in 537 type 2 diabetes patients, separate from the TRIUMPH obesity program OSA data confirmed (ADA June 6, 2026): TRIUMPH-1's nested sleep apnea substudy showed 60.6% AHI reduction from a severe-OSA baseline of 58.6 events/hour TRIUMPH-2 (obesity + diabetes) and TRIUMPH-3 (obesity + cardiovascular disease) results expected later in 2026 Introduction Retatrutide's clinical journey tells a story of escalating and now confirmed efficacy
Conclusion This case report demonstrates that the combination of prolonged water fasting and a GLP-1 receptor agonist is a safe and effective method for short-term substantial weight loss in patients with severe obesity for the purpose of pre-procedural optimization prior to bariatric surgery, and may result in the improvement of multiple chronic diseases including hypertension, insulin resistance, anemia, depression, and diastolic heart failure
IGF-1 DES has a 20-30 minute half-life but is about 10x more potent, making it best for localized, site-specific applications where it's injected directly into target muscles before training
